Directional Versus Orbital Atherectomy Plaque Modification and Luminal Area Assessment of the Femoro-popliteal Artery Via Intravascular Ultrasound

Inclusion Criteria: * Subject's age ≥ 18 years; * Subject (or Legal Guardian if applicable) is willing and able to provide consent before any study-specific test or procedure is performed, signs the consent form, and agrees to attend all required follow-up visits. * Chronic, symptomatic lower limb ischemia defined as Rutherford categories 1-4 * Target lesion(s) located in a superficial femoral or popliteal arteries * Degree of stenosis ≥70% via Qualitative Comparative Analysis (QCA) * Total Lesion Length ≥ 80 mm and ≤ 150 mm * Reference Vessel ≥ 3.0 mm and \<6.5mm * Patent infrapopliteal artery, i.e., single vessel runoff or better with at least one of three vessels patent (\<50% stenosis) to the ankle or foot with no planned intervention. * Subject is an acceptable candidate for percutaneous intervention using the OAS or DAS in accordance with their labeled indications and instructions for use Exclusion Criteria: * Subjects who have an: * Previously stented target lesion/vessel. * Subjects who have undergone prior surgery of the SFA/PA in the target limb to treat atherosclerotic disease. * Presence of aneurysm in the target vessel. * Interventional treatment is intended for in-stent restenosis at the peripheral vascular site. * Target vessel with moderate or severe angulation (e.g., \> 30°) or tortuosity at the treatment segment, that precludes safe advancement of the atherectomy device. * Pre-planned interventional treatment includes planned laser, brachytherapy or atherectomy procedure other than OAS or DAS. * Known hypersensitivity or contraindication to contrast dye that, in the opinion of the investigator, cannot be adequately pre-medicated. * Known hypersensitivity/allergy to antiplatelet, anticoagulant, thrombolytic medications * Platelet count \<80,000 mm3 or \>600,000 mm3 or history of bleeding diathesis. * Patient has any known coagulation disorder, including hypercoagulability * Receiving dialysis or immunosuppressant therapy. * Patient has evidence of intracranial or gastrointestinal bleeding within last 3 months. * Patient has history of severe trauma, fracture, major surgery or biopsy of a parenchymal organ within past 14 days, * Female patient who is pregnant or nursing a child, * Current participation in another investigational drug or device clinical study that has not completed the primary endpoint at the time of randomization/enrollment or that clinically interferes with the current study endpoints.